Torrent Pharma: Synergy benefits, products launches are key
However, the company's March quarter (Q4FY23) results are broadly in line with Street estimates. Analysts say stable margin last quarter, expected gains from Curatio integration and new product launches are reasons for optimism.
Torrent Pharma share price surges 8% to hit a 52-week high; should you buy the stock? Here's what top brokerages say
Torrent Pharmaceuticals' share price surged 8 per cent to hit a 52-week high of 1,851.15 after reporting Q4 net revenue of 2,491 crore, up 17 per cent YoY, and a net profit of 287 crore, compared with a net loss of 118 crore in the previous year.
TORRENT PHARMACEUTICALS LTD. - 500420 - Audio Recording Of Conference Call With Analysts / Investors On Audited Financial Results For The Quarter And Year Ended 31St March, 2023
In continuation to our letter dated 16-May-23 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2023, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording31032023.mp3 Torrent Pharmaceuticals Results Earnings Call for Q4FY23
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. Q4FY23 Quarterly & FY23 Annual Result Announced for Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals announced Q4FY23 results: Q4FY23: Revenue at Rs 2,491 crore up by 17% Gross margins: 72%; Op. EBITDA margins: 29.2% Op. EBITDA at Rs 727 crore was up by 30% Profit after tax at Rs 287 crore FY23: Revenue at Rs 9,620 crore up by 13% Gross margins: 71%; Op. EBITDA margins: 29% Op. EBITDA at Rs 2,842 crore was up by 17% Profit after tax at Rs 1,245 crore Result PDF TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Friday, 23rd June, 2023 as the Record Date for taking record of the Members of the Company entitled for the purpose of payment of final dividend for the year 2022-23, if declared by the Company. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2023 TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Raising of Funds
Board Recommended to the members to obtain enabling approval for issuance of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes for an amount not exceeding ? 5,000 crores in the upcoming Annual General Meeting of the Company. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Dividend Updates
Board Recommended to the members a final dividend of ? 8/- (160%) per equity share of ? 5 each. The final dividend amount, if declared by the Shareholders, is proposed to be paid / dispatched on or around 14th August, 2023. Earlier an interim dividend of ? 14/- (280%) per equity share was paid during the last quarter. TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements), 2015, ("Listing Regulations")
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations")